ライフサイエンスコーパス: adenosine receptor agonist

1 nosine receptors instead of administering an adenosine receptor agonist.

2 eukin-1 (IL-1) in the presence or absence of adenosine receptor agonists.

3 The A(2A) adenosine receptor agonist, 2-p-(2-carboxyethyl)phenylam

4 mobilization stimulated by the nonselective adenosine receptor agonist 5'-(N-ethylcarboxamido)adenos

5 These responses were reproduced by the adenosine receptor agonist 5'-(N-ethylcarboxamido)adenos

6 The nonselective adenosine receptor agonist 5'-(N-ethylcarboxamido)adenos

7 lls were stimulated by focal ejection of the adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

8 Administration of the broad-spectrum adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

9 The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

10 The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

11 ily A(2B) receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

12 The nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

13 es supplemented with adenosine, but not with adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

14 Treatment of mice with the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadensoin

15 t evidence that a small molecule, such as an adenosine receptor agonist, accelerates wound healing in

16 Adenosine receptor agonists and a KATP channel opener we

17 Characterization of the effects of adenosine receptor agonists and antagonists has led to n

18 In the present study, we delivered adenosine receptor agonists and antagonists into the lat

19 Studies using selective adenosine receptor agonists and antagonists suggested th

20 ignificantly altered by dialysis delivery of adenosine receptor agonists and antagonists to the prefr

21 n acute and long-term treatment studies with adenosine receptor agonists and antagonists.

22 variety of well-characterized adenosine and adenosine receptor agonists and antagonists.

23 n unexpected synergistic interaction between adenosine receptor agonists and phosphodiesterase (PDE)

24 diators of preconditioning, e.g., adenosine, adenosine receptor agonists, and adenosine triphosphate-

25 We have used selective adenosine receptor agonists, antagonists, and PDE inhibi

26 PS) in the presence or absence of adenosine, adenosine receptor agonists/antagonists, or CBD.

27 However, efforts to use adenosine receptor agonists are plagued by dose-limiting

28 ns, VEGF expression is slightly increased by adenosine receptor agonists but adenosine A(2) or A(1) r

29 These data demonstrate that adenosine receptor agonists can induce an acute rise in

30 red the effect of topical application of the adenosine receptor agonist CGS-21680 (2-p-[2-carboxyethy

31 epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladeno

32 While the A(1) adenosine receptor agonist CPA and the A(2A) receptor an

33 The lipid-soluble, Al-specific adenosine receptor agonist cyclopentyladenosine, dose-de

34 Adenosine, adenosine-receptor agonists, dibutyryl cAMP, forskolin,

35 loyed to study the functional consequence of adenosine receptor agonists directly on neuronal membran

36 tive chronotropic responses to muscarinic or adenosine receptor agonists do not require activation of

37 hat infusion of either adenosine (ADO) or an adenosine receptor agonist during reperfusion after hypo

38 osine (EC50: 0.5 microM) and NECA (universal adenosine receptor agonist; EC50 0.1 microM) stimulated

39 h clinically relevant agents (eg, NO donors, adenosine receptor agonists, endotoxin derivatives, or o

40 ss-linking, direct influx of calcium, and/or adenosine receptor agonist exposure.

41 R such as forskolin, beta2-adrenergic or A2B-adenosine receptor agonists failed to activate rescued d

42 Adenosine receptor agonists have cardioprotective, cereb

43 In the heart, these effects of A1 adenosine receptor agonists have not been reported.

44 demonstrate that in conscious rabbits the A3 adenosine receptor agonist IB-MECA confers a powerful pr

45 Selective adenosine receptor agonists implicated the A2b adenosine

46 g protection, and they implicate inhaled A2B adenosine receptor agonists in ALI treatment.

47 onamide (IB-MECA), a potent and selective A3 adenosine receptor agonist, in models of myocardial stun

48 sine receptors by adenosine and selective A1 adenosine receptor agonists mimics the protective effect

49 was equivalent to that obtained with the A1-adenosine receptor agonist N6-cyclopentyladenosine (1.56

50 the presence or absence of the nonselective adenosine receptor agonist NECA (5'-N-ethylcarboxamidoad

51 The effect of inosine was mimicked by the adenosine receptor agonist NECA and the A2B receptor ago

52 The selective A(2)-adenosine receptor agonist NECA but not the A(1)-adenosi

53 The non-selective adenosine receptor agonist NECA effectively inhibited IA

54 The adenosine receptor agonist NECA inhibited interferon-gam

55 GABA in the inhibitory actions of A1 and A2a adenosine receptor agonists on rat cerebral cortical neu

56 Adenosine receptor agonists or antagonists were administ

57 secondary to hypoxia was reversed in part by adenosine receptor agonists or reconstitution with solub

58 eta-EP was elevated following treatment with adenosine receptor agonist phenyl-isopropyl adenosine (P

59 (2-phenylisopropyl) adenosine (PIA), an A(1)-adenosine receptor agonist; preconditioned hearts pretre

60 Adenosine receptor agonists produce a wide variety of th

61 Although adenosine receptor agonists produce similar effects, AKI

62 orted that prior treatment with selective A1 adenosine receptor agonists results in a rapid uncouplin

63 f ischemia of the heart with adenosine or A1 adenosine receptor agonists results in uncoupling of A1

64 Although the order of potency of adenosine receptor agonists suggested the involvement of

65 An A2-type adenosine receptor agonist suppresses these effects of I

66 Thus, small, highly permeable drugs (such as adenosine receptor agonists) that transactivate TrkB rec

67 rated that administration of a selective A2A adenosine receptor agonist to CD73-deficient mice result

68 te to inhibit the binding of [3H]CCPA, an A1-adenosine receptor agonist, to brain membranes.

69 reduce the binding of [3H]CGS 21680, an A2a-adenosine receptor agonist, to striatal membranes.

70 Regadenoson, a selective A2A adenosine receptor agonist, was evaluated for tolerabili

71 Tecadenoson is a potent selective A1-adenosine receptor agonist with a dose-dependent negativ

72 The potent A2A-selective adenosine receptor agonist WRC-0470 is a short-acting co

73 Infusions of a potent and selective A2A adenosine receptor agonist, WRC-0470 (0.1 to 3 microgram